Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 66.7%

Neg 0% Neu 0% Pos 66.7%

Cantor Fitzgerald analyst Steve Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Overweight and raises the price target from $4 to $6.